Becton, Dickinson and Company (BDX): Price and Financial Metrics

Becton, Dickinson and Company (BDX)

Today's Latest Price: $246.93 USD

5.43 (2.25%)

Updated May 29 4:32pm

Add BDX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

BDX Stock Summary

  • Becton Dickinson & Co's market capitalization of $65,633,995,287 is ahead of 97.37% of US-listed equities.
  • BDX's went public 34.43 years ago, making it older than 92.87% of listed US stocks we're tracking.
  • In terms of volatility of its share price, BDX is more volatile than merely 1.44% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Becton Dickinson & Co, a group of peers worth examining would be ZTS, CAT, SYK, BSX, and BKNG.
  • BDX's SEC filings can be seen here. And to visit Becton Dickinson & Co's official web site, go to
BDX Daily Price Range
BDX 52-Week Price Range

BDX Stock Price Chart More Charts

BDX Price/Volume Stats

Current price $246.93 52-week high $286.72
Prev. close $241.50 52-week low $197.75
Day low $239.60 Volume 1,925,309
Day high $247.06 Avg. volume 2,252,714
50-day MA $245.55 Dividend yield 1.31%
200-day MA $253.83 Market Cap 66.96B

Becton, Dickinson and Company (BDX) Company Bio

Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for BDX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Becton Dickinson & Co ranked in the 38th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Becton Dickinson & Co ended up being:

  • Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 7. This value is greater than only 11.93% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

HBIO, TARO, ITGR, USPH, and AMED can be thought of as valuation peers to BDX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

BDX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

BDX Latest Social Stream

Loading social stream, please wait...

View Full BDX Social Stream

Latest BDX News From Around the Web

Below are the latest news stories about Becton Dickinson & Co that investors may wish to consider to help them evaluate BDX as an investment opportunity.

Al Gore Sells Credicorp and Adds 3 New Holdings

Former US vice president's firm releases 1st-quarter portfolio Continue reading...

Yahoo | May 27, 2020

Hedge Funds Have Never Been This Bullish On Becton, Dickinson and Company (BDX)

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | May 27, 2020

NYSE: BDX Investor Notice: Lawsuit against Becton, Dickinson and Company announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NYSE: BDX shares. Investors, who purchased shares of Becton, Dickinson and Company (BDX), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On February 27, 2020, a lawsuit was filed against Becton, Dickinson and Company over alleged Securities Laws Violations.

Yahoo | May 27, 2020

Coronavirus Test Kits Market in North America 2020: Analyis of Key Players Abbott Laboratories, Becton Dickinson and Co., Hologic Inc. and Thermo Fisher Scientific Inc.

DUBLIN, May 26, 2020 /PRNewswire/ -- The "Coronavirus Test Kits Market in North America 2020-2024" report has been added to's offering. The coronavirus test kits market in North America is poised to grow by $ 116.27 million during 2020-2024 progressing at a CAGR of…

PR Newswire | May 26, 2020

BD to Present at Jefferies Virtual Healthcare Conference

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 11:00 a.m. ET.

Yahoo | May 26, 2020

Read More 'BDX' Stories Here

BDX Price Returns

1-mo -4.24%
3-mo 4.17%
6-mo -3.87%
1-year 5.42%
3-year 36.57%
5-year 89.01%
YTD -8.91%
2019 22.20%
2018 6.61%
2017 31.24%
2016 9.22%
2015 12.63%

BDX Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full BDX Dividend History

Continue Researching BDX

Here are a few links from around the web to help you further your research on Becton Dickinson & Co's stock as an investment opportunity:

Becton Dickinson & Co (BDX) Stock Price | Nasdaq
Becton Dickinson & Co (BDX) Stock Quote, History and News - Yahoo Finance
Becton Dickinson & Co (BDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1551 seconds.